CPT® Code 80324

Official Description

Amphetamines; 1 or 2

Common Language Description

The CPT® Code 80324 refers to a laboratory test specifically designed to measure the presence of amphetamines in various biological samples, including serum, urine, saliva, hair, and stool. Amphetamines are a class of central nervous system stimulants that are primarily utilized in the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy. This code encompasses the testing for one or two types of amphetamines, which are substances that can have significant effects on mood, energy levels, and cognitive function. It is important to note that certain designer drugs, such as methylenedioxyamphetamine (MDA), methylenedioxymethamphetamine (MDMA, commonly known as Ecstasy), and methylenedioxyethylamphetamine (MDEA, referred to as Eve), not only exhibit stimulant properties but also possess hallucinogenic effects. Due to their potential for addiction and high rates of abuse, amphetamines are closely monitored in clinical and forensic settings. The detection windows for these substances vary by sample type: they can be identified in blood or serum for up to 12 hours post-ingestion, in urine for 2 to 5 days, in saliva for 1 to 5 days, and in hair for as long as 90 days. The testing methodologies employed include high-performance liquid chromatography coupled with tandem mass spectrometry for serum, urine, and stool samples, while hair samples are analyzed using gas chromatography/mass spectrometry. Saliva testing is conducted through a rapid immunochromatographic assay. The specific code 80324 is utilized when testing for one or two amphetamines, whereas codes 80325 and 80326 are designated for testing three or four, and five or more amphetamines, respectively.

1. Indications

The laboratory test represented by CPT® Code 80324 is indicated for the detection and quantification of amphetamines in various biological samples. This test is typically performed in the following scenarios:

Assessment of Substance Abuse: The test is utilized to evaluate individuals suspected of abusing amphetamines or related substances, particularly in clinical, legal, or employment settings.
Monitoring Treatment Compliance: It is used to ensure that patients prescribed amphetamines for conditions such as ADHD or narcolepsy are adhering to their treatment regimens.
Evaluation of Overdose: The test may be indicated in cases of suspected overdose to determine the presence and concentration of amphetamines in the body.

2. Procedure

The procedure for conducting the laboratory test associated with CPT® Code 80324 involves several key steps to ensure accurate measurement of amphetamines:

Sample Collection: Biological samples, such as serum, urine, saliva, hair, or stool, are collected from the patient. The choice of sample type may depend on the clinical context and the specific substances being tested.
Sample Preparation: The collected samples undergo preparation, which may include processes such as centrifugation for serum or urine, and appropriate handling techniques for hair and saliva to ensure integrity and prevent contamination.
Analytical Testing: The prepared samples are subjected to specific analytical methods. Serum, urine, and stool samples are analyzed using high-performance liquid chromatography coupled with tandem mass spectrometry, which allows for precise identification and quantification of amphetamines. Hair samples are tested using gas chromatography/mass spectrometry, while saliva samples are evaluated through a rapid immunochromatographic assay.
Result Interpretation: After the analytical testing is completed, the results are interpreted by qualified laboratory personnel. The presence and concentration of amphetamines are reported, which can assist healthcare providers in making informed clinical decisions.

3. Post-Procedure

Post-procedure considerations for the laboratory test associated with CPT® Code 80324 include the proper handling and storage of biological samples prior to testing, as well as the timely reporting of results to ensure that healthcare providers can act on the findings. Patients may not require specific post-procedure care, but it is essential for healthcare providers to discuss the implications of the test results with patients, especially in cases of positive findings for amphetamines. Follow-up actions may include further evaluation, counseling, or adjustments to treatment plans based on the results obtained from the test.

Short Descr	DRUG SCREEN AMPHETAMINES 1/2
Medium Descr	DRUG SCREEN QUANT AMPHETAMINES 1 OR 2
Long Descr	Amphetamines; 1 or 2
Status Code	Not Valid for Medicare Purposes
Global Days	XXX - Global Concept Does Not Apply
PC/TC Indicator (26, TC)	9 - Not Applicable
Multiple Procedures (51)	9 - Concept does not apply.
Bilateral Surgery (50)	9 - Concept does not apply.
Physician Supervisions	09 - Concept does not apply.
Assistant Surgeon (80, 82)	9 - Concept does not apply.
Co-Surgeons (62)	9 - Concept does not apply.
Team Surgery (66)	9 - Concept does not apply.
Diagnostic Imaging Family	99 - Concept Does Not Apply
APC Status Indicator	Code Not Recognized by OPPS when submitted on Outpatient Hospital Part B Bill Type (12x/13x)
Type of Service (TOS)	5 - Diagnostic Laboratory
Berenson-Eggers TOS (BETOS)	T2D - Other tests - other
MUE	1

90	Reference (outside) laboratory: when laboratory procedures are performed by a party other than the treating or reporting physician or other qualified health care professional, the procedure may be identified by adding modifier 90 to the usual procedure number.
GZ	Item or service expected to be denied as not reasonable and necessary